TA Scan Trial Feasibility Use Case

Clinical trial feasibility plays a critical role in the success of research, particularly in complex studies like phase 3 trials for non-small cell lung cancer (NSCLC) patients with EGFR mutations. These trials require a precise balance of internal insights and external data to optimize country and site selection, anticipate recruitment challenges, and streamline planning. TA Scan’s Trial Feasibility Flex provides a powerful solution, integrating high-quality global trial intelligence with sponsor-specific parameters to deliver actionable insights and predictive enrollment scenarios.

In a recent NSCLC trial targeting EGFR mutations, Trial Feasibility Flex enabled the sponsor to analyze historical data, assess site capacity, and evaluate the competitive landscape across multiple countries. This approach supported evidence-based decisions, identifying optimal regions for recruitment while accounting for regulatory delays and competing trials. By leveraging customizable simulation tools, the sponsor forecasted enrollment timelines, mitigated site-level risks, and achieved more reliable recruitment projections.